On July 24, 2024, Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, announced the closing of an oversubscribed $100 million Series C financing. Proceeds from the financing round will be used to commence two Phase 2 clinical trials for the company’s lead program, ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist that was well-tolerated and demonstrated CNS target engagement in a Phase 1 study. In the second half of 2024, Autobahn plans to initiate Phase 2 trials designed to provide biological and clinical proof-of-concept of ABX-002 as an adjunctive treatment for patients with major depressive disorder (MDD) and patients with bipolar disorder depression. MDD and bipolar disorder are highly prevalent, debilitating, and life-threatening mental illnesses that affect more than 20 million people and 7 million people in the U.S. alone, respectively.

Wilson Sonsini Goodrich & Rosati advised Autobahn Therapeutics on IP matters related to the Series C financing. The Wilson Sonsini team includes Ingo Hardt, Mike Hostetler, and Jim Malecha.

For more information, please see Autobahn Therapeutics' press release.